Keyphrases
Adjunctive Therapy
14%
Clinical Aspects
14%
Continuous Glucose Monitor
14%
Controlled Crosses
14%
Dapagliflozin
100%
Disease Duration
14%
Exogenous Glucose
14%
Glucose Clamp
14%
Glucose Variability
28%
Glycated Hemoglobin
28%
Hyperglycemic Clamp
14%
Hyperinsulinemic
14%
Hypoglycemia
42%
Hypoglycemia Risk
14%
Hypoglycemia Unawareness
100%
Once-daily
14%
Placebo
28%
Placebo-controlled
14%
Randomized Double-blind
14%
Short-term Use
100%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
14%
Symptom Response
14%
Treatment Duration
14%
Type 1 Diabetes Mellitus (T1DM)
100%
Type I Diabetes
100%
Washout Period
14%
Medicine and Dentistry
Antidiabetic Agent
27%
Awareness
100%
Clinical Feature
9%
Continuous Glucose Monitor
9%
Dapagliflozin
100%
Disease Duration
9%
Glycated Hemoglobin
18%
Hypoglycemia
100%
Insulin Dependent Diabetes Mellitus
100%
Patient with Type 1 Diabetes
9%
Placebo
27%
Sodium Glucose Cotransporter 2 Inhibitor
9%
Type 1 Diabetes
36%
Pharmacology, Toxicology and Pharmaceutical Science
Antidiabetic Agent
27%
Clinical Feature
9%
Dapagliflozin
100%
Disease Duration
9%
Glycosylated Hemoglobin
18%
Hypoglycemia
100%
Insulin Dependent Diabetes Mellitus
100%
Placebo
27%
Sodium Glucose Cotransporter 2 Inhibitor
9%
INIS
avoidance
14%
diseases
14%
glucose
100%
hemoglobin
28%
hypothesis
14%
men
14%
monitors
14%
patients
28%
people
100%
reduction
14%
risks
14%
sodium
14%
symptoms
14%
washout
14%